SENSEI BIOTHERAPEUTICS INC. - COMMON STOCK

Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

10 May 2022 06:30:01 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports Full Year 2021 Financial Results and Business Highlights

10 Mar 2022 06:30:01 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Appoints William Ringo, MBA, as Chair of Board of Directors

09 Mar 2022 15:05:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference

03 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in Citi’s 2022 Virtual Immuno-Oncology Summit

11 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces Executive Promotions

06 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Named a Winner of Comparably’s Best CEO Award

16 Dec 2021 08:01:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces Addition to the Nasdaq Biotechnology Index

13 Dec 2021 15:01:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference

19 Nov 2021 15:02:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a pH-Selective Anti-VISTA Antibody, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

12 Nov 2021 06:02:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights

09 Nov 2021 07:54:48 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in the Berenberg Virtual U.S. CEO Conference on Tuesday, November 9, 2021

03 Nov 2021 08:01:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Proprietary Anti-VISTA Antibody, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

01 Oct 2021 07:05:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program

04 Aug 2021 06:45:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Appoints Kristian Humer to its Board of Directors

02 Aug 2021 07:01:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal Antibody and Nanobody Programs

28 Jun 2021 15:05:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck

19 May 2021 16:03:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports First Quarter 2021 Results and Provides Business Update

12 May 2021 06:41:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Appoints Maura Gillison, M.D., Ph.D., and Richard Ulevitch, Ph.D., to its Immuno-Oncology Advisory Board

05 May 2021 07:05:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Appoints Jessie M. English, Ph.D. to its Board of Directors

05 Apr 2021 07:00:01 By Nasdaq GlobeNewswire